INFU
InfuSystem Holdings, Inc.
INFU has the edge over NVO overall, supported by stronger fundamentals and stronger valuation.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
INFU Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
INFU's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
INFU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $14.79 | — |
| Cheap | 28x | $12.19 | -18% |
| Current | 34x | $14.79 | — |
| Fair | 50x | $21.97 | +49% |
| Expensive | 333x | $146 | +890% |
Historical ranges are pointers, not guarantees.
INFU's PE is in its cheap range at 34x. If earnings grow as analysts expect, today's price would be 25x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over INFU in the historical PE scenario, which offers more potential upside but is not a forecast.
INFU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect INFU's earnings to grow and its profitability to improve, with its revenue holding steady.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
INFU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.59 | +34% |
| Q3 2026 | $0.44 | +63% |
| Q2 2026 | $0.40 | +67% |
| Q1 2026 | $0.37 | +147% |
| Q4 2025 | $0.31 | +182% |
| Q3 2025 | $0.27 | +286% |
| Q2 2025 | $0.24 | +1100% |
| Q1 2025 | $0.15 | +1400% |
| Q4 2024 | $0.11 | +175% |
INFU has the edge over NVO on earnings, with stronger typical year-over-year growth.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
INFU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.6M | +3% |
| Q2 2026 | $36.9M | +2.6% |
| Q1 2026 | $33.7M | -3% |
| Q4 2025 | $36.2M | +7% |
| Q3 2025 | $36.5M | +3.3% |
| Q2 2025 | $36M | +6.8% |
| Q1 2025 | $34.7M | +8.5% |
| Q4 2024 | $33.8M | +6.5% |
INFU's revenue grew through 2024 and has held roughly level since: $38M last quarter, up 3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +2.2 points |
| Q2 2026 | 11% | +0.8 points |
| Q1 2026 | 4.7% | +2.9 points |
| Q4 2025 | 10% | +2.5 points |
| Q3 2025 | 10% | +1.2 points |
| Q2 2025 | 10% | +5 points |
| Q1 2025 | 1.8% | +4.4 points |
| Q4 2024 | 7.7% | +3.8 points |
INFU's operating margin was 13% last quarter, up 2.2 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over INFU on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over INFU on profitability, with a higher operating margin.
INFU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.3M | +22% |
| Q2 2026 | $6.7M | -1.6% |
| Q1 2026 | $813K | -51% |
| Q4 2025 | $7M | -5.5% |
| Q3 2025 | $8.4M | -14% |
| Q2 2025 | $6.8M | +244% |
| Q1 2025 | $1.6M | +746% |
| Q4 2024 | $7.4M | +74% |
INFU generated $25M in free cash flow over the past year, up 2.1% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over INFU on cash flow, with more consistent year-over-year improvement.
INFU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +152K shares |
| 1 year | +0.6% | +126K shares |
| 3 years | -3% | -647K shares |
| 5 years | +2.4% | +494K shares |
| Available history | +1.1% | +233K shares |
INFU has 21M diluted shares, up 0.6% from a year ago, despite $6M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $605,000 |
| Q2 2026 | $3.5M |
| Q1 2026 | $809,000 |
| Q4 2025 | $1.3M |
| Q3 2025 | $2.2M |
| Q2 2025 | $3.5M |
| Q1 2025 | $2.9M |
| Q4 2024 | $199,000 |
INFU spent $6M buying back its own shares over the past year, down 28% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over INFU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
INFU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.7x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.2x | Healthy |
INFU has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
INFU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.2 | Overbought |
| Stochastic | 84.8 | Overbought |
INFU's weekly RSI is 73 (overbought) and its Stochastic is 85 (overbought).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
INFU PE vs Healthcare Sector
| Metric | INFU | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 30% above |
| PE % | 31 | 29 | 2 pts above |
INFU is trading at 34x earnings, a 30% premium to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over INFU on valuation relative to its sector.
INFU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.7 | 8.3% above |
| 20 week MA | $12.1 | 22% above |
| 50 week MA | $10.3 | 44% above |
| 100 week MA | $8.93 | 66% above |
| 200 week MA | $8.82 | 68% above |
INFU has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
INFU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.22 | $19.0 | +131% |
| 2021 | $19.0 | $16.9 | -11% |
| 2022 | $16.9 | $8.50 | -50% |
| 2023 | $8.50 | $10.5 | +24% |
| 2024 | $10.5 | $8.14 | -23% |
| 2025 | $8.14 | $8.96 | +10% |
| 2026 YTD | $8.96 | $14.8 | +65% |
INFU has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.